Re­gen­eron con­tin­ues reign atop the Covid treat­ment field with ex­pand­ed EUA for low­er dose sub­cu­ta­neous ver­sion of mAb cock­tail

The FDA on Fri­day au­tho­rized a new, low­er-dose ver­sion of Re­gen­eron’s Covid-19 mon­o­clon­al an­ti­body cock­tail for those with Covid-19 who are at high-risk of pro­gress­ing to hos­pi­tal­iza­tion.

The new dose is half the orig­i­nal­ly au­tho­rized dose, but the eas­i­er-to-ad­min­is­ter sub­cu­ta­neous ver­sion may not be the game-chang­er that ex­perts once en­vi­sioned. Re­gen­eron said in a state­ment that the com­bo “should be ad­min­is­tered by in­tra­venous (IV) in­fu­sion” and sub­cu­ta­neous in­jec­tions “are an al­ter­na­tive when IV in­fu­sion is not fea­si­ble and would lead to a de­lay in treat­ment.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN